Author: digi

Pre-Submission Briefing Book: Structure, Evidence & Reviewer-Friendly Writing

November 3, 2025

Pre-Submission Briefing Book: Structure, Evidence & Reviewer-Friendly Writing How to Build the Pre-Submission Briefing Book: Structure, Evidence, and Writing that Makes Reviewers Say “Yes” Outcome-Oriented Briefing Books: Design for Decisions, Not Description Start with the decision, then backfill the evidence The most effective pre-submission briefing books begin with what you want the Agency to decide…

US Regulatory Submissions

NHS/NIHR Site Enablement: Capacity, Governance, Templates

November 3, 2025

digi

NHS/NIHR Site Enablement: Capacity, Governance, Templates NHS/NIHR Site Enablement: Building Capacity, Proving Governance, and Using Templates That Survive Inspection Why NHS/NIHR enablement decides UK enrollment velocity—and how to make it inspection-ready for US/UK/EU reviewers The enablement problem in one sentence Most UK programs stall not at feasibility, but between local confirmations and the first clinic…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Clinical Protocol in INDs: Risk, Endpoints & Amendment Strategy

November 3, 2025

digi

Clinical Protocol in INDs: Risk, Endpoints & Amendment Strategy Designing the Clinical Protocol for an IND: Risk Controls, Endpoints That Stand Up to Review, and a Smart Amendment Strategy Why the IND protocol is your single most leveraged document—and how to make it decision-ready Anchor to patient protection and decision utility The clinical protocol submitted…

US Regulatory Submissions

Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks

November 2, 2025

digi

Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks Cut Delays Fast: How to Tame Prior Authorization, Imaging Queues, and Scheduling Bottlenecks Without Losing Compliance Why cycle-time kills enrollment—and the exact levers that buy back weeks in US/UK/EU programs The three hidden clocks that decide whether you randomize on time Across high-enrolling studies, cycle-time failures track back…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

CMC for INDs: Quality Module Essentials for Early-Phase Programs

November 2, 2025

digi

CMC for INDs: Quality Module Essentials for Early-Phase Programs CMC for INDs: Building an Early-Phase Quality Module That FDA Accepts and Sites Can Execute Why CMC drives first-patient-in: the early-phase essentials and how to show them Outcome focus: fitness-for-purpose over perfection For an initial Investigational New Drug application, Chemistry, Manufacturing and Controls (CMC) is about…

US Regulatory Submissions

IND Safety Reporting: What Triggers, Timelines, Forms & Best Practices

November 2, 2025

digi

IND Safety Reporting: What Triggers, Timelines, Forms & Best Practices IND Safety Reporting in the US: Triggers, Timelines, Forms, and Proven Practices for Inspection-Ready Programs Why IND safety reporting is mission-critical—and what “good” looks like in practice Regulatory intent: rapid detection, rapid communication, zero ambiguity IND safety reporting is designed to protect participants and preserve…

US Regulatory Submissions

US vs UK Recruitment Tactics That Actually Move Numbers

November 2, 2025

digi

US vs UK Recruitment Tactics That Actually Move Numbers US vs UK Recruitment Tactics That Actually Move Numbers (and Survive Inspection) Outcomes, not activity: the recruitment playbook that lifts randomizations on both sides of the Atlantic Why “more outreach” isn’t a strategy Recruitment fails when teams mistake volume for velocity. More emails, more postcards, more…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

IND Application Checklist: Modules, Forms, Timelines & Common Deficiencies

November 2, 2025

digi

IND Application Checklist: Modules, Forms, Timelines & Common Deficiencies IND Application Checklist: A US-First Guide to Modules, Forms, Timelines, and Fixing Common Pitfalls What an “inspection-ready” IND looks like—and why it matters for US/UK/EU sponsors Outcome definition: faster first-patient-in without regulatory rework An inspection-ready Investigational New Drug submission balances scientific credibility, procedural compliance, and operational…

US Regulatory Submissions

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)

November 2, 2025

digi

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Predictable Outcomes (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…

US Regulatory Submissions

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations

November 2, 2025

digi

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations Enrollment Funnel Analytics: How to Find the Leaks and Lift Randomizations with a System You Can Defend Why enrollment funnels decide study success—and how analytics turns “maybe” into predictable randomizations From activity to outcomes: measuring the right moments in the funnel Every clinical program lives or dies…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment